Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication NEUPOGEN is a leukocyte growth factor indicated to Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever ( 1.1 ) Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment… FDA label
Also known as Injection of Filgrastim, of Filgrastim
Filgrastim · 4 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| pegfilgrastim | EXPERIMENTAL | Pegfilgrastim given once after induction chemotherapy |
| filgrastim | ACTIVE_COMPARATOR | Filgrastim given daily after induction chemotherapy |
| Name | Type | Description |
|---|---|---|
| filgrastim | DRUG | Filgrastim given daily after induction chemotherapy |
| pegfilgrastim | DRUG | Pegfilgrastim given once after induction chemotherapy |
| Paclitaxel | DRUG | 1-hour IV infusion once weekly for 12 to 14 weeks |
| Vinorelbine | DRUG | escalating doses administered intravenously over 6-10 minutes for 12-14 weeks |
| Radiation | RADIATION | Radiotherapy for 5 consecutive days every other week (weeks 1, 3, 5, 7, 9, 11, 13)starting on same day as first dose of protocol chemotherapy |
| Epoetin alfa | DRUG | - |
| Zidovudine | DRUG | - |
Inclusion * Histologically confirmed de novo AML as evidenced by absence of an antecedent hematologic disease of \> 1 months duration, prior chemotherapy, prior radiation therapy or myelodysplastic cytogenetics (as per exclusion criteria) * Life expectancy, with treatment, \> 3 months * Age \> 18 y...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
Filgrastim is being studied in breast cancer, HIV infections, and myeloid leukemia. It has been tested as supportive care alongside chemotherapy and antiretroviral regimens, including in patients with advanced breast cancer, acute myeloid leukemia, and HIV-related cytopenias. It remains an investigational therapy in these settings.
Filgrastim targets CSF3R, also known as the granulocyte colony-stimulating factor receptor. It acts as an agonist at this receptor, mimicking the natural G-CSF ligand to stimulate neutrophil production and function. This mechanism underlies its investigation as supportive care in chemotherapy and HIV-related neutropenia.
Filgrastim is developed by Amgen Inc., which trades on the Nasdaq under the ticker AMGN. Amgen is the sponsor associated with the clinical development of this agent across the studied indications.
Filgrastim is in Phase 1 development. It is investigational and has not been approved for the indications studied here. The clinical program includes Phase 1 and Phase 2 trials, all of which are completed, with no active trials currently listed.
Filgrastim has been evaluated in completed trials including NCT00724386 in advanced breast cancer, NCT00114764 comparing pegfilgrastim with filgrastim in acute myeloid leukemia, NCT00002255 in HIV and AIDS-related complex, and NCT00002126 for prevention of grade 4 neutropenia in HIV infection.
Yes, Filgrastim is also known as Injection of Filgrastim. These names refer to the same agent, which is developed by Amgen Inc. (AMGN) and targets CSF3R as an agonist. It is being studied in breast cancer, HIV infections, and myeloid leukemia.